Healthcare

DataMEDS AI Agrees to Acquire TBIA Cancer Testing Assets, Subject to Court Approval

DataMEDS AI says it has agreed to acquire the TBIA Cancer AI blood-testing platform and other assets from the estate of Todos Medical, with completion subject to Court Approval.

Published:
Reading Time
4 min

DataMEDS AI, Inc. (NASDAQ:MEDS) has agreed to acquire selected assets from the estate of Todos Medical Ltd., including a blood-testing platform developed for breast and colorectal cancer. The proposed transaction is subject to Court Approval, and the tests have not been cleared or approved by the U.S. Food and Drug Administration or made commercially available in the United States.

#Assets covered by the agreement

The proposed acquisition includes Todos Medical’s Total Biochemical Infrared Analysis, or TBIA, Cancer AI platform. The assets include the TM-B1 and TM-B2 tests for breast cancer and the TM-C1 test for colorectal cancer. The technology was originally developed at Ben Gurion University in Israel.

DataMEDS also said the agreement covers Todos’ licence for the LymPro™ Alzheimer’s diagnostic blood test and 100% of the shares in Todos Medical Singapore PTE Ltd. The Singapore company previously held an interest in Pathnova Labs PTE Ltd., which was exchanged for shares in Archerfish Precision Diagnostics Pte Ltd. after Pathnova merged with Angsana Molecular & Diagnostics Laboratory.

#How the TBIA platform works

The platform uses Fourier-transform infrared spectroscopy to examine biochemical information in blood plasma and peripheral blood mononuclear cell components. DataMEDS said the digitised information is intended to support multiple algorithms from one blood draw, without using antibodies or other biological inputs.

The company said the same technology had also been used to distinguish viral infections from bacterial infections. Previous CE Marks in Europe covered the breast cancer and colorectal cancer tests, although the announcement does not state that those marks currently remain in effect.

#Planned Helomics programme

DataMEDS said the spectroscopy assets are intended to be transferred to Helomics, its wholly owned subsidiary and Pittsburgh-based CLIA-certified clinical laboratory. The planned work includes reassessing historical links between TBIA results, biopsy findings and imaging results.

According to the company, Helomics plans to obtain blood samples through its oncologist network under institutional review board-approved protocols and with patient consent. Data generated alongside the ChemoFx® Assay programme would be used to support validation of the TBIA platform and a potential launch as a laboratory-developed test before any subsequent FDA submissions.

DataMEDS said the ChemoFx® Assay has been granted two unique CPT codes and has begun receiving coverage decisions. The company said this programme could generate revenue while also producing data for TBIA validation; no revenue figure was provided.

#Regulatory and clinical limitations

The TBIA tests are not FDA-cleared or FDA-approved and are not currently available commercially in the United States. DataMEDS identified future regulatory authorisation, laboratory-developed test development and validation as matters that remain uncertain.

The company also said that the tests’ clinical performance has not been established in prospective clinical studies. This includes their sensitivity, specificity, ability to identify early-stage cancers and ability to detect multiple cancer types from one blood draw.

Other matters identified by DataMEDS include obtaining appropriately consented samples, meeting data privacy and security requirements, securing reimbursement, physician and patient adoption, and determining pricing and cost of goods sold. The company also cited competition, intellectual-property issues, the value and assignment of the LymPro™ licence, and the funding needed to integrate and develop the acquired assets.

#Patent position and transaction conditions

DataMEDS said issued patents in the United States and Europe cover the TBIA platform and provide market exclusivity into at least 2034. The company separately identified the scope, validity, enforceability and expiration of those patents as subject to risk and uncertainty.

The agreement with the estate of Todos Medical is subject to Court Approval. DataMEDS also identified possible requirements for court, liquidator or third-party approvals and consents, as well as the ability to obtain good title to and transfer the acquired patents, know-how, data, algorithms and equipment. Further transaction terms, conditions, contingencies and obligations apply beyond those set out here.

Gerald Commissiong, Interim Co-CEO of DataMEDS, said the company believes the platform could support analysis of several cancer types from a single blood sample. He also said the technology may help examine the body’s response to cancer at an early stage. The release states that these capabilities have not been established in prospective clinical studies.

#Company background

DataMEDS describes itself as a healthcare company combining technology, pharmacy, pharmaceutical-adjacent and telemedicine operations through health information technology platforms. Its business includes the EinsteinRx™ artificial intelligence platform, the PharmacyChain™ platform and pharmacy-related services.

Helomics operates a CLIA-certified laboratory focused on precision oncology. Its ChemoFx® Assay tests live tumour cells against chemotherapy agents to provide patient-specific information for oncologists. Helomics also operates a Predictive Oncology innovation division that combines a biobank of tumour samples with artificial intelligence and multi-omic data. The ChemoFx® Assay is a laboratory-developed test and has not been cleared or approved by the FDA.

#Key Takeaways

  • DataMEDS AI has agreed to acquire the TBIA Cancer AI platform and other assets from the estate of Todos Medical.
  • The platform includes TM-B1 and TM-B2 breast cancer tests and the TM-C1 colorectal cancer test.
  • Completion is subject to Court Approval, along with any other required approvals, consents and closing conditions.
  • The TBIA tests have not been cleared or approved by the FDA and are not commercially available in the United States.
  • DataMEDS said issued U.S. and European patents provide market exclusivity into at least 2034, while clinical performance remains unestablished in prospective clinical studies.

Original source: Read original article

Frequently Asked Questions